How Follicular Dendritic Cells Shape the B-Cell Antigenome

Jan Kranich1* and Nike Julia Krautler2*

1 Institute for Immunology, Ludwig Maximilian University Munich, Munich, Germany; 2 Institute of Microbiology, ETH Zurich, Zurich, Switzerland

Follicular dendritic cells (FDCs) are stromal cells residing in primary follicles and in germinal centers of secondary and tertiary lymphoid organs (SLOs and TLOs). There, they play a crucial role in B-cell activation and affinity maturation of antibodies. FDCs have the unique capacity to bind and retain native antigen in B-cell follicles for long periods of time. Therefore, FDCs shape the B-cell antigenome (the sum of all B-cell antigens) in SLOs and TLOs. In this review, we discuss recent findings that explain how this stromal cell type can arise in almost any tissue during TLO formation and, furthermore, focus on the mechanisms of antigen capture and retention involved in the generation of long-lasting antigen depots displayed on FDCs.

Keywords: follicular dendritic cells, tertiary lymphoid organs, antigen, B-cell responses, antigenome, germinal centers, antigen trapping

REQUIREMENTS FOR FDC DEVELOPMENT

After the first mentioning of FDCs little more than half a decade ago, initial experiments, mainly using bone marrow chimeras (6, 7), indicated that FDCs are of stromal, radioresistant, and likely sessile character. In the meantime, extensive data were brought forward attributing important functions to FDCs in B-cell responses, such as the provision of the chemokine CXCL13, essential to allure B cells into the follicles in a CXCR5-dependent manner (8). Interestingly, the dependence of B cells and FDCs was found to be mutual; in the absence of B cells, FDCs did not form (9). B cells were shown to be the main source for lymphotoxins (LT) and tumor necrosis factors (TNF), which upon binding to their respective receptors, LTβR and TNFR1, present on the surface of FDCs and their precursors, acted as potent drivers of FDC maturation (9–16). Furthermore, after the initial generation of FDCs...
sustained LT signaling was shown to be required for keeping them in a differentiated and functional state (17).

While it was soon recognized that FDCs are a central component of B-cell follicles in spleen and in lymph nodes, their appearance was not limited to SLOs. FDCs were also shown to contribute to non-encapsulated lymphoid structures, such as the isolated lymphoid follicles of the intestine (18). In addition to this, FDCs were frequently observed during certain chronic inflammations in non-lymphoid tissues. As a result of an unresolved inflammation during autoimmunity (e.g., rheumatoid arthritis) or during chronic infections (e.g., hepatitis C infection), such tissues can undergo remodeling into TLOs (19–21), containing FDCs and microanatomically segregated T and B cell areas. Autoimmune diseases and chronic inflammations with FDC involvement are summarized in Table 1. The notion that FDCs can possibly be generated everywhere in the body suggests that their precursors sport either considerable motility or that they are derived from a non-migratory ancestor. Bone marrow chimera experiments, where FDCs in spleen and LN were generated from host cells, added evidence to the latter hypothesis (6, 7). The idea that FDCs could have differentiated from a local precursor, was further supported by the finding that FDCs shared markers with other stromal cells of SLOs and TLOs and showed similarities with fibroblasts and mesenchymal cells (1, 22, 23). In parabiont experiments, where the blood circulation of two mice was surgically connected for 3 months, no FDCs had been generated from the surgically attached counterpart (24). This also corroborated a model of a non-migratory and rather local precursor, giving rise to FDCs.

In a murine model of chronic inflammation, transgenic overexpression of LTα under the rat insulin promoter (RIP-Lta) leads to the formation of TLOs in kidneys, including fully matured FDCs (25–27). When these mice were treated with LTβR-Ig decoy receptors (17) to remove mature (renal) FDCs followed by transplantation of their kidneys into recipient mice, this led to the reformation of FDCs exclusively derived from cells of the transplanted donor kidneys. This finding proved that, even during the generation of TLOs, FDC precursors are tissue-intrinsic (25). Detailed analysis of the expression of the FDC-expressed molecule Mfge8 [FDC-M1; (28)] during splenic organogenesis as well as in mice lacking FDCs, further suggested that the earliest FDC precursor was located in the splenic perivascular space. These putative precursors expressed PDGFRβ and SMA. Since mature FDCs do not express PDGFRβ, lineage-tracing experiments (using Pdgfrb-Cre mice) were performed and confirmed that FDCs had derived from such PDGFRβ-positive precursors. The expression of PDGFRβ and SMA as well as their localization indicated that these cells were in fact mural vascular cells. Depending on the localization (surrounding small capillaries or larger vessel) and their appearance, mural cells are divided into single-layered pericytes or several layers of vascular smooth muscle cells. Mural cells can be isolated from the stromal-vascular fraction of white adipose tissue (29). The transplantation of PDGFRβ-positive cells, sort-purified from the stromal-vascular fraction, into the kidney capsule of mice lacking endogenous FDCs gave rise to artificial lymph nodes containing fully differentiated FDCs. This showed that FDCs are generated from perivascular cells. The ubiquity of such perivascular cells and, therefore, likely FDC precursors also explains why it is possible for FDCs to arise in any tissue or organ (25). It remains to be shown, whether any mural cell can give rise to FDCs or whether it needs to be derived from specific tissues, such as the adipose tissue. This is of particular interest as LN anlagen usually are inserted within fat pads. Indeed stimulation of LTβR signaling inhibits adipocyte differentiation and promotes a fibroblast-like phenotype (30).

Follicular dendritic cells are not the sole stromal cell of SLOs. Fibroblast reticular cells (FRCs) contribute to the structure and function of the T-cell zone, while marginal reticulocyte cells (MRCs) are important for the function and the structure of the splenic marginal zone (MZ) (31). Recently, novel stromal subpopulations were identified, such as the versatile stromal cells at the T cell–B cell border of inflamed B-cell follicles [VSCs; (32)] and the CXCL12-expressing reticular cells of the GC dark zone [CRCs; (32)]. FDCs, FRCs, and MRCs share the expression of many markers, such as LTβR, BP-3, VCAM-1, and ICAM-1 (25, 33–35), which could also suggest a common precursor. To identify this potential precursor, labeling experiments were performed with fetal mesenchymal progenitors of spleen and lymph nodes. Splenic mesenchymal precursors were followed using either Nkx2-5-Cre or Islet1-Cre reporter mice and found to contribute to FDCs, FRCs, MRCs, and mural cells (36). A reporter mouse for neural crest cells (Wnt-1-Cre), embryonic progenitor cells that give rise to mesenchymal structures of the head and the neck region, was used to test if FDCs in auricular and cervical lymph nodes were derived from such cells. Indeed, Jarjour et al. could show that FDCs as well as MRCs and other stromal cells can be labeled with this technique (24). While the authors did not confirm if the Wnt-1-Cre reporter also labeled PDGFRβ+SMA+ perivascular precursors in lymph nodes, FRCs, and precursors thereof, have been attributed a pericyte-like character and reside as CCL21+CCL19+PDGFRβ+SMA+ cells in perivascular locations of inguinal and popliteal lymph nodes (35, 37). The transplantation of fetal splenic Nkx2-5-reporter positive cells or adult adipose PDGFRβ stromal vascular cells generated artificial lymph nodes, further supporting the idea that these early precursors can contribute to all stromal compartments and

### Table 1 Human diseases with lymphoid neogenesis.

| Autoimmune diseases                                      | Chronic allograft rejection                                      |
|----------------------------------------------------------|------------------------------------------------------------------|
| Rheumatoid arthritis (88–91)                             | Organ transplantation (118, 119)                                   |
| Hashimoto’s thyroiditis and Graves’ disease (92–95)       |                                                                   |
| Myasthenia gravis (96–98)                                |                                                                   |
| Sjogren’s syndrome (99–101)                              |                                                                   |
| Multiple sclerosis (102–104)                             |                                                                   |
| Cryptogenic fibrosing alveolitis (105, 106)               |                                                                   |
| Systemic lupus erythematosus (107, 108)                  |                                                                   |
| Infectious diseases                                      | Other chronic inflammations                                      |
| Chronic hepatitis C (109, 110)                           | Ulcerative colitis (120, 121)                                     |
| Helicobacter pylori-induced gastritis (111–115)           | Atherosclerosis (122, 123)                                       |
| Chronic Lyme disease (116, 117)                          |                                                                   |
| Cancer                                                   |                                                                   |
| Non-small cell lung cancer (124, 125)                    |                                                                   |
| Colorectal carcinoma (126)                               |                                                                   |
| Ductal breast carcinoma (127, 128)                       |                                                                   |
| Melanoma (metastasis) (129)                              |                                                                   |
| Mucosal-associated lymphoid tissue lymphoma (115)         |                                                                   |
| Non-small cell lung cancer (124, 125)                    |                                                                   |
| Colorectal carcinoma (126)                               |                                                                   |
| Ductal breast carcinoma (127, 128)                       |                                                                   |
| Melanoma (metastasis) (129)                              |                                                                   |
| Mucosal-associated lymphoid tissue lymphoma (115)         |                                                                   |
even includes stromal organizer cells able to initiate lymph node anlagen (25, 36). A model for FDC development is illustrated in Figure 1.

THE DISCOVERY OF FDCs

As mentioned above, the deposition of antigen within SLOs was studied extensively in the 1960s, using radioactively labeled microbial antigens, such as isolated flagellin derived from *Salmonella*. Immunofluorescent detection of antigens, which was a very new technique at that time, was also used in some of the studies (38, 39). A common observation was that even though most of the antigen was endocytosed by phagocytic cells, some remained extracellularly on the surface of cells, whose identity was obscure at that time. Miller and Nossal described that within the follicle cell surface-bound antigen was trapped on fine processes of cells, which at that point they believed to be a phagocytic cell subset (39). However, later electron-microscopy studies clarified that antigen was rather associated with the dendritic processes of non-phagocytic reticular cells and that these cells formed large web-like structures (3, 40, 41).

While further studies in the following years dealt with the exact distribution of antigen within the lymph node and GCs, the precise nature of these antigen-retaining reticular cells remained unclear for several more years. Various different names were used for these cells by the different laboratories that studied them. So they were also sometimes referred to as dendritic macrophages or dendritic reticular cells (40, 42). However, the common feature recognized by all these studies (43) was the extraordinary ability of these cells to retain antigen on their cell surface. Hence, these cells clearly differed from the typical phagocytic cells. In 1978, Chen et al. published a detailed anatomical and functional study of these cells. They introduced the name “FDCs” owing to their long cytoplasmic processes, and not because of relations to classical dendritic cells (DCs) (44). The authors realized that the name may not be ideal and suggested that at a later time point, when more would become known about these cells the name might need to be reconsidered (44). However, even when it became evident that FDCs lacked MHC class II expression, a molecule expressed at high levels by conventional, hematopoietic DCs, the name FDCs persisted (45) with the consequence that FDCs are still often confused with conventional DCs.

Using electron-dense tracers, Chen et al. showed that FDCs, unlike macrophages, do not actively endocytose (43, 44), a view that has recently been challenged by a study that showed that FDCs endocytose ICs, which they acquire from non-cognate B cells. In contrast to macrophages, ICs endocytosed by FDCs retain their native form and recycle to the cell surface (46), a feature essential for long-term antigen display. Electron microscopy further revealed that FDCs have unique cellular structures, including large, irregular nuclei, containing little heterochromatin, and only few organelles. One striking feature was that FDCs only had small cell bodies, while their cytoplasm extended into many filiform dendrites, forming an extensive net-like structure, which seemed to act like a cap covering the secondary follicle (43, 44).

IMMUNE-COMPLEX TRAPPING – THE CARDINAL FUNCTION OF FDCs

In the 1960s, researchers tried to address the molecular requirements for antigen retention in B-cell follicles. Nossal et al.

---
compared antigen distribution in non-immunized rats with those that either had received a passive or an active immunization against *Salmonella* prior to administration of radiolabeled *Salmonella* flagellin. Strikingly, they observed that immunization greatly influenced the distribution of antigen within the lymph node. Rats that were actively or passively immunized before they received radiolabeled antigen had a faster and more intense accumulation of antigen in their follicles than non-immunized animals. The increase in follicular antigen deposition seen in immunized rats led the authors to conclude that an opsonin was responsible for the efficient targeting of antigen to the follicle, and that this opsonin was likely to be an antibody (47). This observation was also confirmed to hold true in other species; Humphrey et al. immunized rabbits with non-microbial antigens (radiolabeled hemocyanin or human serum albumin). Prior to injection of radiolabeled antigen, the rabbits were either immunized with a single injection of unlabeled antigen, received repeated injections of antigen shortly after birth (inducing antigenic tolerance) or had remained untreated (naive). While uptake of radiolabeled antigen by medullary sinus macrophages did not differ between the three treatments, no antigen was retained by FDCs in the follicles of naive rabbits. Furthermore, tolerized rabbits had no detectable levels of antibody and showed no follicular antigen retention by FDCs. Thus, it was established that for the follicular retention of antigen the presence of antigen-specific antibodies was crucial (48).

Still, some studies had shown that low-level retention of antigen also occurred in non-primed animals (47). Hence, some doubts remained, whether the “follicular opsonin” was the antibody itself or if another, antibody-induced substance, was involved.

Experiments by Williams then showed that a substance produced by lymphocytes was important: he had previously seen a diminished uptake of *Salmonella* flagellin in lymphoid follicles after depletion of peripheral lymphocytes by partial irradiation with shielded bone marrow (49). This observation had led him to assume that lymphocytes produced substances with opsonizing activity. To test this hypothesis, he monitored the accumulation of flagellin in follicles in the absence of peripheral lymphocytes and assessed how the application of normal rat serum or antibody influenced follicular antigen deposition. A decline in the retention of radiolabeled antigen was observed from day 5 after irradiation onward. Jaroslow and Nossal had previously shown that FDCs are highly resistant to irradiation, so an impairment of FDC function could be excluded as the reason for reduced antigen accumulation following irradiation (50). To restore the antigen retention, normal rat serum or anti-flagellar immune serum was injected. Immune serum significantly improved antigen trapping, as did normal rat serum, but for the latter 25-times more volume was required. By contrast, fetal calf serum did not improve the antigen uptake in follicles, showing that serum-dependent antigen trapping was species specific. Furthermore, neither injection of lymphocytes nor supernatant from cultured lymphocytes showed an effect. While this study had pitfalls mainly due to the irradiation, still an important conclusion could be drawn from this study; immune serum contained large-amounts of the “follicular opsonin,” also supporting the idea, that antibodies might be the crucial opsonin. However, the finding that non-immune serum also was able to restore antigen retention in the follicle even though at a much lower efficiency, suggested the presence of additional opsonins (49).

While it became generally accepted that antigen–antibody complexes were crucial for efficient targeting of native antigen to FDCs, years had to pass until other factors essential for IC-trapping, namely complement, were identified. Only in 1974 Pepsy found that depletion of the complement component C3 by cobra venom factor, strongly reduced T-cell-dependent B-cell responses to sheep red blood cells (SRBC), illustrating the central role of C3 in the induction of antibody production (51). One year later evidence that complement was required to retain antigen in the GC came from Papamichail et al., who reported that complement inhibition with cobra venom factor blocked trapping of aggregated IgG in the splenic follicle (52). In line with this, Klaus and Humphrey observed that chronic depletion of C3 inhibited memory B-cell formation and concluded that the assembly of an antigen–antibody–C3 complex on FDCs is crucial for B-cell memory (53). More than 20 years later, the complement receptors 1 and 2 (CR1, CR2) were found to be responsible for capturing of C3-containing ICs (54). In humans, two separate genes encode for CR1 and CR2; in mice, however, the Cr2 locus encodes for both CR1 (CD35) and CR2 (CD21) and expression of either CR1 or CR2 is determined by alternative splicing. CR2 binds degradation products of C3, such as iC3bm C3d,g, C3d, while CR1 binds C3b and C4b (55). All mature B cells express CR2, but particularly high levels are found on MZ B cells. FDCs predominantly express CR1 (56). On B cells, CR2 acts as a B-cell receptor (BCR) co-receptor. Fusing antigen with one or more copies of C3d lowered the amount of antigen needed to induce B-cell responses up to 10,000 fold in a CR2-dependent manner (57). Several studies have shown that FDCs utilize CR1/2 to retain antigen on their surface (54, 56, 58, 59).

In addition to complement receptors, FDCs use other receptors to bind ICs. *Ex vivo* IC-trapping experiments on splenic cryosections of immunized mice were tested in presence or absence of serum for the retention of ICs. In presence of serum, most trapping depended on CR1/2, since CR1/2 blocking antibodies dramatically reduced IC-capturing. However, in absence of complement (without serum), some trapping on a subset of FDCs still occurred. This residual trapping could be blocked with anti-FcγRIIβ antibodies (59). The importance of Fc-receptors for IC-trapping by FDCs was also confirmed *in vivo*, since Fcgr2b<sup>−/−</sup> mice showed significantly reduced IC-trapping, and although primary antibody responses are unaltered in mice with FcγRIIβ-deficient FDCs, recall responses are diminished (60).

In summary, the crucial components to deliver antigen to FDCs are antigen-specific antibodies and complement factors. But how exactly antigen reaches FDCs has remained unclear for a long time.

**MECHANISMS OF ANTIGEN DELIVERY TO FDCs**

Already in 1983, Szakal et al. described antigen transport cells (ATCs) that supposedly transported antigen from the subcapsular
sinus to the FDCs. These cells were non-phagocytic and had morphological similarities with FDCs, leading to the assumption that these cells might be pre-FDCs, an observation which remained unconfirmed (61, 62).

It was shown that in the spleen MZ B cells capture IgM-containing immune complexes (IgM-ICs) and transport and deposit them onto FDCs within the B-cell follicle (63, 64). This transfer was dependent on complement and CR1/CR2, and mice deficient for those factors, showed no accumulation of IgM-ICs on FDCs. Still, how would antigen be brought to FDCs in lymph nodes that lack MZ B cells? This was revealed by two-photon microscopy studies (65, 66). Phan et al. showed that in lymph nodes subcapsulary sinus (SCS) macrophages capture immunofluorescently labeled ICs [Phycoerythrin:ICs; (65)]. These macrophages monitor the lymph fluid that arrives in the subcapsular sinus, bind large amount of ICs and have little endocytic activity. ICs travel along the processes of these macrophages and transfer antigen onto non-cognate follicular B cells in a complement receptor-dependent manner. Subsequently, ICs are shuttled from the B cells onto FDCs (66). Mechanisms of IC delivery to FDCs are depicted in Figure 2.

**THE ROLE OF FDC-BOUND ICs IN B-CELL RESPONSES**

Immune complexes bound by FDCs are organized in a bead-like formation, as the so-called iccosomes. These IC-coated bodies can be endocytosed by tingible body macrophages (TBMφs) and B cells (67). The effect on B-cell activation, GC development, affinity maturation, and memory B-cell maintenance of FDC-bound ICs has been studied in great detail (1). It is generally accepted that FDC function as storage of native antigen. During the GC reaction, high-affinity B cells access antigen, internalize, process, and display it to T helper cells, thereby receiving BCR stimulation as well as additional T helper cell-derived survival signals (68, 69). Early studies assessing the influence of FDCs on B-cell activation were performed in vitro using FDC-enriched clusters. They showed that only in the presence of FDCs, ICs (in the form of isolated iccosomes) were able to strongly activate B cells, evidenced by substantially increased antibody production against the cognate antigen. Hence, FDCs stimulate B cells via FDC-bound antigen, but also via antigen-independent FDC products (70). In addition to this, Boes et al. found that in the absence of secreted IgM antigen trapping by FDCs was reduced and GC formation as well as antibody affinity maturation impaired (71).

Based on these and other studies, the view that FDCs can take part in B-cell activation and play an important role during affinity maturation by displaying native antigen and by presenting survival signals to B cells and that they are involved in memory B-cell development has become generally accepted.

However, this view has been challenged by results obtained from mice that produce only membrane bound IgM, hence, unable to make ICs. These mice showed normal GC formation, despite absent IC-trapping by FDCs (72). Furthermore, CR1/2-deficient mice are also able to form GCs and B cells of such mice even undergo affinity maturation, although numbers and size of the GCs were reduced and antibody levels much lower than those in their wild-type counterparts (73, 74). The role of FDCs and ICs trapped by them has then been critically discussed (75, 76). Haberman and Shlomchik concluded that the role of FDCs in providing non-specific support for the GC reaction is undisputed, but ICs on FDCs might only be important under certain conditions. By contrast, Kosco-Vilbois stresses that immune responses are still most efficient in the presence of ICs on FDCs. Thus, an efficient vaccine should maximize the deposition of ICs on FDCs.

**SPECULATIONS ON ADDITIONAL FUNCTIONS OF FDCs**

While the consequences of IC-trapping by FDCs are still not fully understood, other functions of FDCs have been identified. The expression of cytokines directs B cells to primary and

---

**FIGURE 2 | IC acquisition.** In the spleen (left panel), non-cognate marginal zone (MZ) B cells capture ICs, consisting of antigen, IgM or IgG, and C3 degradation products (C3d and C3b), from the blood stream (1). MZ B cells, which have captured ICs in a C3d/CR2-dependent fashion, then migrate into the follicle, where they transfer the ICs onto FDCs, which bind them via C3b and CR1 (2). The ICs are then released from the MZ B cell (3). In the lymph node (right panel), subcapsulary sinus macrophages (SCSMφ) capture ICs consisting of antigen, IgM or IgG, and C3d and C3b degradation products from the lymph (1). SCSMφ migrate into the follicle and transfer ICs to follicular (FO) B cells in a CR2-dependent manner (2). Subsequently, FO B cells transfer the ICs onto FDCs (3, 4).
secondary follicles (1, 77), they supply B cells with trophic factors, such as B-cell activating factor [BAFF; (78)] or instruct TBMϕs to remove apoptotic GC B cells through the secretion of the phosphatidylserine-binding bridging molecule Mfge8 (28). The main functions of FDCs are shown in Figure 3.

However, we still think that apart from the role of FDCs in establishing the correct follicular microarchitecture and enabling the formation of GCs (79), one of the most important functions of FDCs lies in the trapping of antigen and activation of B cells. FDCs are the only known cell type that extensively trap ICs for long periods of time in a way that protects native antigen from degradation (46). Therefore, FDCs shape the antigenome – the sum of all native antigens that can be detected by B cells, in primary and secondary follicles. However, although evidence is lacking, we postulate that FDCs might not only trap antigen in the form of ICs, but also in a way that does not require the presence of antigen-specific antibodies, hence, would allow antigen trapping also in individuals that have not previously been exposed to the antigen.

The reasons why we think a trapping mechanism independent of antibodies might exist are the following. It is still widely unknown how naive B cells are activated in a non-immune host, where ICs are absent. While in immune hosts not only the capturing of antigen by FDCs is dependent on ICs but also the antigen transport into the follicle requires ICs. It has been shown that native antigen is captured by subcapsulary sinus macrophages (SCSMϕ) in lymph nodes (66) and by MZ B cells in the spleen (63) in an IC-dependent manner. These cells then transport the antigen inside the follicle and deposit it onto FDCs, where it then can activate naive B cells.

While natural IgM is certainly of importance to control infections before high-affinity antibodies are generated (80), natural IgM does not seem to be sufficient to deposit easily detectable amounts of antigen onto FDCs (47–49). Furthermore, it is known that some viral glycoproteins (such as HIV gp120) quite successfully evade recognition by antibodies, e.g., by shielding their epitopes with glycans (81). This makes it very hard for the infected host to develop antibodies against such antigens. In such a case, it seems counterintuitive that antibody-containing ICs are required to mount a B-cell response, especially since such an IC would potentially mask the rare epitope needed for the initial BCR engagement in order to activate the cognate B cell.

Another study showed that soluble antigen readily diffuses through the follicle and is capable of activating B cells (82). However, this study used adoptively transferred BCR transgenic B cells, with the consequence that an unphysiological high number of antigen-specific B cells are located in the follicles. If soluble antigen is efficient enough to trigger B-cell responses, in a more natural setting, where antigen, as well as antigen-specific B cells are limiting, remains an open question.

Using BCR transgenic B cells specific for HEL and DCs that were pulsed with HEL, Qi et al. showed in a two-photon
microscopy approach that DCs can carry unprocessed antigen into the lymph node and activate cognate B cells in extrafollicular regions (83). If this is a general mechanism of antigen transport into the lymph node and how efficiently this activates B cells under more physiological conditions remains to be addressed.

While all these possibilities are certainly able to trigger B-cell responses, the presentation of antigen via FDCs (46) seems to be the most intuitive and effective way to bring antigen in contact with antigen-specific B cells.

Secondary lymphoid organs are considered to be specialized structures to ensure that a DC, presenting pathogen-derived peptides via MHC class II molecules, finds and activates the rare cognate T cell that recognizes these peptides. Accordingly, we postulate that efficient mechanisms play no or only a minor role in the initial priming of naive antigen-specific B cells.

To do so FDCs retain native antigen sufficiently long, protected from degradation and at the same time concentrating it at the location where many B cells reside. This strongly increases the likelihood of antigen-encounter by the rare cognate B cell. Such a mechanism is especially important when antigen and cognate B cells are combined with a high frequency of antigen-specific antibodies to the FDCs within B-cell follicles ensures that a rare cognate B cell meets its specific antigen. To do so FDCs retain naive antigen sufficiently long, protected from degradation and at the same time concentrating it at the location where many B cells reside. This strongly increases the likelihood of antigen-encounter by the rare cognate B cell. Such a mechanism is especially important when antigen and cognate B cells are limited. In artificial systems where large quantities of antigen are combined with a high frequency of antigen-specific B cells (like in models that use BCR transgenic B cells), naive B cells might readily get in contact with their antigen even without the need of FDCs. Thus, although, it is often assumed that FDCs play no or only a minor role in the initial priming of naive B cells (84), we, therefore, postulate that efficient mechanisms exist, which allow FDCs to capture, retain, and present antigen in non-immune hosts in an antibody-independent manner and, thus, can play an important role in the initial activation of B cells.

CONCLUDING REMARKS

The biology of FDCs has been extensively studied, nevertheless, many questions regarding these cells remain unanswered.

Although there have been some controversies about their importance in the past (75, 76), FDCs are now generally accepted as indispensable for efficient, high-affinity antibody responses. Importantly, FDCs are the only known cell type that functions as a long-term antigen depot. We think it is important to understand what the consequences of such antigen storage are for the activation of B cells, especially during chronic inflammations, where FDC-containing TLOs arise in non-lymphoid tissues, e.g., during rheumatoid arthritis (85). There, FDCs might function as a tissue-specific depot of antigen. Although, little is known, how antigen is acquired by FDCs in TLOs, it might differ from antigen acquisition in lymph nodes or spleen. Also the nature of the antigen might be different from antigen that circulates in the blood stream and is then captured by FDCs in the spleen or from antigen that is transported by the lymph flow to the draining lymph node. It is possible that FDCs in TLOs might preferentially capture antigens that are released in the affected tissue by local tissue damage and that this drives GC formation and chronic inflammation or autoimmunity in affected tissues. Hence, FDCs have long been considered an attractive target for therapeutic intervention, e.g., by administering LTβR-Ig fusion proteins, which lead to FDC ablation (86). However, clinical trials assessing efficacy of LTβR-Ig fusion proteins (Baminercept) in RA patients did not show a measurable effect in treated patients (87). Other studies, assessing, for example, the efficacy of Baminercept to treat Sjögren’s syndrome are still ongoing (study ID NCT01552681).

Being “dynamic antigen libraries” (3), FDCs hold valuable information about antigens and antigen epitopes that trigger antibody responses. This information would be of relevance in autoimmunity, chronic inflammation, and cancers with intratumoral TLOs to identify antigenic triggers of disease or cancer antigens that can be used to fight tumors. However, there are currently no techniques available to screen and define the antigenome of FDCs. It would be important to develop techniques that allow the isolation of the FDC antigenome. Subsequent proteomic analysis of the FDC-trapped antigens would provide valuable information that could be exploited for development of novel vaccines or for therapeutics against chronic inflammation.

AUTHOR CONTRIBUTIONS

JK wrote the abstract, introduction, and following chapters: The discovery of FDCs, Immune complex trapping – the cardinal function of FDCs, Mechanisms of antigen delivery to FDCs, The role of FDC-bound ICs in B-cell responses, Speculations on additional functions of FDCs, and Concluding remarks. He also prepared Figures 1, 2, and 3. NK wrote the chapter “Requirements for FDC development,” and prepared Table 1 and Figures 1, 2, and 3.

REFERENCES

1. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol (2008) 20(1):14–25. doi:10.1016/j.smim.2007.12.001
2. Rodda LB, Bannard O, Ludewig B, Nagasawa T, Cyster JG. Phenotypic and morphological properties of germinal center dark zone Cxcl12-expressing reticular cells. J Immunol (2015) 195(10):4781–91. doi:10.4049/jimmunol.1501191
3. Mitchell J, Abbot A. Ultrastructure of the antigen-retaining reticulum of lymph node follicles as shown by high-resolution autoradiography. Nature (1965) 208(5009):500–2. doi:10.1038/208500b0
4. Aguzzi A, Kranich J, Krautler NJ. Follicular dendritic cells: origin, phenotype, and function in health and disease. Trends Immunol (2014) 35(3):105–13. doi:10.1016/j.it.2013.11.001
5. Heesters BA, Myers RC, Carroll MC. Follicular dendritic cells: dynamic antigen libraries. Nat Rev Immunol (2014) 14(7):495–504. doi:10.1038/nri3689
6. Humphrey JH, Grennan D, Sundaram V. The origin of follicular dendritic cells in the mouse and the mechanism of trapping of immune complexes on them. Eur J Immunol (1984) 14(9):859–64. doi:10.1002/eji.1830140916
7. Yoshida K, Kaji M, Takahashi T, van den Berg TK, Dijkstra CD. Host origin of follicular dendritic cells induced in the spleen of SCID mice after transfer of allogeneic lymphocytes. Immunology (1995) 84(1):117–26.
8. Cyster JG, Ansel KM, Reif K, Eklund EH, Hyman PL, Tang HL, et al. Follicular stromal cells and lymphocyte homing to follicles. *Immunol Rev* (2002) 184:11–31. doi:10.1080/0105281021000021183

9. Futterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfleffer K. The lympho-toxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. *Immunity* (1998) 9(1):59–70. doi:10.1016/S1074-7613(00)80588-9

10. Fu X, Chaplin DD. Development and maturation of secondary lymphoid tissues. *Annu Rev Immunol* (1999) 17:399–433. doi:10.1146/annurev.immunol.17.1.399

11. Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA. Distinct roles in lymphoid organogenesis for lymphotin alpha and beta revealed in lympho-toxin beta-deficient mice. *Immunity* (1997) 6(4):491–500. doi:10.1016/S1074-7613(00)80292-7

12. De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Maritahasan, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotin. *Science* (1994) 264(5159):703–7. doi:10.1126/science.8171322

13. Fu X, Molina H, Matsumoto M, Huang G, Min J, Chaplin DD. Lymphotoxin-alpha (LTalpha) supports development of splenic follicular structure that is required for IgG responses. *J Exp Med* (1997) 185(12):2111–20. doi:10.1084/jem.185.12.2111

14. Pasparakis M, Alexopoulos L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cells follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. *J Exp Med* (1996) 184(4):1397–411. doi:10.1084/jem.184.4.1397

15. Le Hir M, Bluthmann H, Kosco-Vilbois MH, Muller M, di Padova F, Moore M, et al. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor 1 signaling. *J Exp Med* (1996) 183(5):2367–72. doi:10.1084/jem.183.5.2367

16. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. Lymphotoxin-beta receptor signaling through NF-kappaB2-RelB pathway reprograms adipocyte precursors as lymph node stromal cells. *Immunity* (2012) 37(4):721–34. doi:10.1016/j.immuni.2012.06.010

17. van den Haan JM, Mebius RE, Krala G. Stromal cells of the mouse spleen. *Front Immunol* (2012) 3:201. doi:10.3389/fimmu.2012.00201

18. Mionnet C, Mondor I, Jordura A, Loosveld M, Maurizio J, Arengani ML, et al. Identification of a new stromal cell type involved in the regulation of inflamed B cell follicles. *Proc Natl Acad Sci U S A* (1992) 89(21):10036–40. doi:10.1073/pnas.89.21.10036

19. Kraanich K, Krautler NJ, Heinen E, Polymenidou M, Bridel C, Schildknecht A, et al. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Msf8. *J Exp Med* (2008) 205(6):1293–302. doi:10.1084/jem.20071019

20. Nakamura N, Takeuchi O, Akira S, Kawai T. Toll-like receptor signaling. *Immunity* (2007) 7(3):212–20. doi:10.1016/j.immuni.2007.02.023
51. Kranich and Krautler
How FDCs Shape the Antigenome

52. 63. Szakal AK, Kosco MH, Tew JG. A novel in vivo follicular dendritic cell-derived iccosome-mediated mechanism for delivery of antigen to antigen-processing cells. *J Immunol* (1988) 140(2):341–53.

54. MacLeran JC. Germinal centers. *Annu Rev Immunol* (1994) 12:117–39. doi:10.1146/annurev.iim.12.041994.001001

55. Victoria GD, Nussenzwieg MC. Germinal centers. *Annu Rev Immunol* (2012) 30:429–57. doi:10.1146/annurev-immunol-020711-075032

56. Wu J, Qin D, Burton GE, Szakal AK, Tew JG. Follicular dendritic cell-derived antigen and accessory activity in initiation of memory IgG responses in vitro. *J Immunol* (1996) 157(8):3404–11.

57. Boes M, Esau C, Fischer MB, Schmidt T, Carroll M, Chen J. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. *J Immunol* (1998) 161(10):6767–87.

58. Hannum LG, Haberman AM, Anderson SM, Schlomchik MJ. Germinal center initiation, variable gene region hypermutation, and mutant B cell selection without detectable immune complexes on follicular dendritic cells. *J Exp Med* (2000) 192(7):931–42. doi:10.1083/jem.192.7.931

59. Ahearn JM, Fischer MB, Croix D, Goerg S, Ma M, Xia J, et al. Disruption of the C2r locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. *Immunology* (1996) 94(3):251–62. doi:10.1046/s1074-7613(00)00433-1

60. Chen Z, Korolov SB, Gendelman M, Carroll MC, Kelsoe G. Humoral immune responses in C2r-/- mice: enhanced affinity maturation but impaired antibody persistence. *J Immunol* (2000) 164(9):4522–32. doi:10.4049/jimmunol.164.9.4522

61. Haberman AM, Schlomchik MJ. Reassessing the function of immune-complex retention by follicular dendritic cells. *Nat Rev Immunol* (2003) 3(9):757–64. doi:10.1038/nri1178

62. Kosco-Vilbois MH. Are follicular dendritic cells really good for nothing? *Nat Rev Immunol* (2003) 3(9):764–9. doi:10.1038/nri1179

63. Muppidi JR, Lu E, Cyster JG. The protein-coated receptor P2RYY and follicular dendritic cells promote germinal center confinement of B cells, whereas SIPR3 can contribute to their dissemination. *J Exp Med* (2015) 212(13):2213–22. doi:10.1084/jem.20151250

64. Lesley R, Xu Y, Kallfel S, Hess DM, Schwab SR, Hu BR, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on RAFF. *Immunology* (2004) 20(4):441–53. doi:10.1111/j.1440-1711.2003.03659.x

65. Wang X, Cho B, Suzuki K, Xu Y, Green JA, An J, et al. Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. *J Exp Med* (2011) 208(12):2497–510. doi:10.1084/jem.20111449

66. Jayasekera JP, Moseman EA, Carroll MC. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. *J Virol* (2007) 81(7):3488–94. doi:10.1128/JVI.02128-06

67. West AP Jr, Scharf L, Scheid JF, Klein E, Bjorkman PJ, Nussenzwieg MC. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. *Cell* (2014) 156(4):633–48. doi:10.1016/j.cell.2014.01.052

68. Pape KA, Catron DM, Itano AA, Jenkins MK. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. *Immunology* (2007) 26(4):491–502. doi:10.1111/j.1440-1711.2007.02011.x

69. Qi H, Egen JG, Huang AF, Germain RN. Extracellular activation of lymph node B cells by antigen-bearing dendritic cells. *Science* (2006) 312(5780):1672–6. doi:10.1126/science.1125703

70. Tew KG, Wu J, Fakher M, Szakal AK, Qin D. Follicular dendritic cells beyond the necessity of T-cell help. *Trends Immunol* (2001) 22(7):361–7. doi:10.1016/S1471-4906(01)09142-1

71. Ruddle NH. Lymphatic vessels and tertiary lymphoid organs. *J Clin Invest* (2012) 124(3):953–9. doi:10.1172/JCI71611

72. Fava RA, Notidis E, Hunt J, Szanya V, Ratcliffe N, Ngam-Ek A, et al. A role for the lymphotixin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. *J Immunol* (2003) 171(1):115–26. doi:10.4049/jimmunol.171.1.115

73. Genovese MC, Greenwald MW, Alloway JA, Baldassare AR, Chase W, Newman C, et al. Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) results of the phase 2B study in the TNF-IR population. *Arthritis Rheum* (2009) 60(Suppl 10): 417. doi:10.1002/art.25500
123. Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. *J Pathol* (2001) 193(2):263–9. doi:10.1002/1096-9896(2000)9999-9999<;AID-PATH774>3.0.CO;2-N

124. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. *J Clin Oncol* (2008) 26(27):4410–7. doi:10.1200/JCO.2007.15.0284

125. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *Am J Respir Crit Care Med* (2014) 189(7):832–44. doi:10.1164/rcrm.201309-1611OC

126. Vayrynen JP, Sajanti SA, Klintrup K, Makela J, Herzig KH, Karttunen TJ, et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. *Int J Cancer* (2014) 134(9):2126–35. doi:10.1002/ijc.28533

127. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. *J Immunol* (2002) 169(4):1829–36. doi:10.4049/jimmunol.169.4.1829

128. Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. *Cancer Res* (2003) 63(12):3275–80.

129. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. *Cancer Res* (2012) 72(16):3997–4007. doi:10.1158/0008-5472.CAN-12-1377

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a shared affiliation, though no other collaboration, with one of the authors [J.K.] and states that the process nevertheless met the standards of a fair and objective review.

**Copyright © 2016 Kranich and Krautler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**